Status:
UNKNOWN
PCSK9 Inhibitor Treatment for Patients With SPG5
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Hereditary Spastic Paraplegia Type 5
Eligibility:
All Genders
14-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Spastic paraplegia type 5 (SPG5) is a rare subtype of hereditary spastic paraplegia, a highly heterogeneous group of neurodegenerative disorders defined by progressive neurodegeneration of the cortico...
Eligibility Criteria
Inclusion
- Age 14-80 years
- Probands with clinically manifest hereditary spastic paraplegia
- Genetically confirmed diagnosis of SPG5
Exclusion
- Comprised treatment with statins 3 months prior to enrolment
- Contraindications to PCSK9 inhibitor therapy
- Pregnancy was excluded in women of childbearing age
Key Trial Info
Start Date :
September 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 3 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04101643
Start Date
September 29 2019
End Date
January 3 2023
Last Update
November 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology , First Affiliated Hospital Fujian Medical University
Fuzhou, China